Revathy Duvedi and Dilip Nalla
ICON plc, USA
Scientific Tracks Abstracts: J Biom Biostat
The purpose of the paper is to share methods and nuances of how to analyze clinical trial data in oncology. The following will be shared: Kaplan-Meier analyses, handling of missing data, competing risks related to overall survival, issues related to proportional hazards model assumption violations, interval censoring and recurrence event analyses. SAS codes and Macros will also be shared. Typically these topics are spread out in various papers. We will provide a consolidated paper documenting all the issues and methods. The intention is for the paper to be used as a roadmap or blueprint on how to approach analyses in oncology trials covering a variety of indications.
Revathy Duvedi has been in the Pharma/Biotech industry for more than 26 years and have been Icon for more than 10 years. She has been focusing primarily on Oncology therapeutic area for more than 10 years.